{
    "id": 29613,
    "fullName": "BRAF N486_T491delinsK",
    "impact": "indel",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "BRAF N486_T491delinsK results in a deletion of 6 amino acids in the protein kinase domain of the Braf protein from amino acids 486 to 491, combined with the insertion of a lysine (K) at the same site (UniProt.org). N486_A491delinsK confers a gain of function to Braf, as indicated by increased ERK activation and transformation of cultured cells (PMID: 30867592).",
            "references": [
                {
                    "id": 14632,
                    "pubMedId": 30867592,
                    "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 673,
        "geneSymbol": "BRAF",
        "terms": [
            "BRAF",
            "B-raf",
            "B-RAF1",
            "BRAF1",
            "NS7",
            "RAFB1"
        ]
    },
    "variant": "N486_T491delinsK",
    "createDate": "03/28/2019",
    "updateDate": "03/28/2019",
    "referenceTranscriptCoordinates": {
        "id": 178990,
        "transcript": "NM_004333",
        "gDna": "chr7:g.140778036_140778050del15",
        "cDna": "c.1458_1472del15",
        "protein": "p.N486_T491delinsK",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib) inhibited viability of transformed cells expressing BRAF N486_T491delinsK in culture (PMID: 30867592).",
            "molecularProfile": {
                "id": 31686,
                "profileName": "BRAF N486_T491delinsK"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14632,
                    "pubMedId": 30867592,
                    "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16572,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Langerhans cell histiocytosis harboring BRAF N486_T491delinsK (PMID: 30867592; NCT01953926).",
            "molecularProfile": {
                "id": 31686,
                "profileName": "BRAF N486_T491delinsK"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60073,
                "name": "lymphatic system cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14632,
                    "pubMedId": 30867592,
                    "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31686,
            "profileName": "BRAF N486_T491delinsK",
            "profileTreatmentApproaches": [
                {
                    "id": 19379,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF N486_T491delinsK"
                },
                {
                    "id": 19378,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF N486_T491delinsK"
                },
                {
                    "id": 19377,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF N486_T491delinsK"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 178990,
            "transcript": "NM_004333",
            "gDna": "chr7:g.140778036_140778050del15",
            "cDna": "c.1458_1472del15",
            "protein": "p.N486_T491delinsK",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 178989,
            "transcript": "XM_005250045",
            "gDna": "chr7:g.140778036_140778050del15",
            "cDna": "c.1458_1472del15",
            "protein": "p.N486_T491delinsK",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}